UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

Journal of the American Society of Nephrology, 2018-10, Vol.29 (10), p.2458-2470

2018

Volltextzugriff (PDF)

Association de l’enzalutamide et du tolvaptan : un risque d’inefficacité thérapeutique

Le Pharmacien Clinicien, 2024-06, Vol.59 (2), p.e74-e74

2024

Volltextzugriff (PDF)

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan

American journal of kidney diseases, 2019-03, Vol.73 (3), p.354-362

2019

Volltextzugriff (PDF)

Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct

American journal of physiology. Renal physiology, 2024-01, Vol.326 (1), p.F57-F68

2024

Volltextzugriff (PDF)

Response criteria of tolvaptan for the treatment of hepatic edema

Journal of gastroenterology, 2018-02, Vol.53 (2), p.258-268

2018

Volltextzugriff (PDF)

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Toxicological sciences, 2017-01, Vol.155 (1), p.61-74

2017

Volltextzugriff (PDF)

Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　― Results From the K-STAR Study

Circulation Journal, 2017/12/25, Vol.82(1), pp.159-167

2018

Volltextzugriff (PDF)

Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations: Clinical article

Journal of neurosurgery, 2013-12, Vol.119 (6), p.1478-1483

2013

Volltextzugriff (PDF)

Tolvaptan for Volume Management in Heart Failure

Pharmacotherapy, 2019-04, Vol.39 (4), p.473-485

2019

Volltextzugriff (PDF)

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

Toxicology letters, 2023-01, Vol.373, p.148-151

2023

Volltextzugriff (PDF)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)

Journal of gastroenterology, 2020-08, Vol.55 (8), p.800-810

2020

Volltextzugriff (PDF)

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy

International journal of molecular sciences, 2024-02, Vol.25 (4), p.2088

2024

Volltextzugriff (PDF)

Validated liquid chromatography coupled to tandem mass spectrometry method for simultaneous quantitation of tolvaptan and its five major metabolites in human plasma

Annals of clinical biochemistry, 2019-05, Vol.56 (3), p.387-396

2019

Volltextzugriff (PDF)

Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration

Biological and Pharmaceutical Bulletin, 2018, Vol.41 (7), p.1014-1016

2018

Volltextzugriff (PDF)

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer

International journal of molecular sciences, 2024-08, Vol.25 (15), p.8402

2024

Volltextzugriff (PDF)

Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial

Medicine (Baltimore), 2019-02, Vol.98 (7), p.e14540

2019

Volltextzugriff (PDF)

Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure

Internal Medicine, 2019, pp.1697-18

2019

Volltextzugriff (PDF)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

Nephron (2015), 2023-04, Vol.147 (3-4), p.152-157

2023

Volltextzugriff (PDF)

Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial

JACC. Heart failure, 2020-03, Vol.8 (3), p.157-168

2020

Volltextzugriff (PDF)

Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial

American journal of kidney diseases, 2024-09, Vol.84 (3), p.275-285.e1

2024

Volltextzugriff (PDF)

Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis

Digestive diseases (Basel), 2020-01, Vol.38 (1), p.38-45

2020

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　― A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial

Circulation Journal, 2021/09/11, pp.CJ-21-0430

2021

Volltextzugriff (PDF)

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V 2 receptor-independent pathway

British journal of pharmacology, 2019-05, Vol.176 (9), p.1315-1327

2019

Volltextzugriff (PDF)

Spectrophotometric Method and Its Validation for Tolvaptan in Its Bulk and Marketed Formulation Including Stress Studies

INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY, 2023-03, Vol.13 (1), p.216-220

2023

Volltextzugriff (PDF)

1 – 25 von 1.027

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(897)
Mit Volltextzugriff
(894)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Tolvaptan
(893)
Science & Technology
(746)
Life Sciences & Biomedicine
(726)
Humans
(514)
Male
(287)
Female
(252)
Heart Failure
(217)
Antidiuretic Hormone Receptor Antagonists - Therapeutic Use
(214)
Hyponatremia
(200)
Urology & Nephrology
(192)
Middle Aged
(183)
Benzazepines - Therapeutic Use
(175)
Tolvaptan - Therapeutic Use
(173)
Aged
(170)
Cardiovascular System & Cardiology
(152)
Patients
(144)
Cardiac & Cardiovascular Systems
(143)
Diuretics
(140)
Kidney Diseases
(140)
Medicine
(138)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

Association de l’enzalutamide et du tolvaptan : un risque d’inefficacité thérapeutique

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct

Response criteria of tolvaptan for the treatment of hepatic edema

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　― Results From the K-STAR Study

Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations: Clinical article

Tolvaptan for Volume Management in Heart Failure

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy

Validated liquid chromatography coupled to tandem mass spectrometry method for simultaneous quantitation of tolvaptan and its five major metabolites in human plasma

Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer

Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial

Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial

Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial

Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis

Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　― A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V 2 receptor-independent pathway

Spectrophotometric Method and Its Validation for Tolvaptan in Its Bulk and Marketed Formulation Including Stress Studies

Suchergebnisse filtern